Skip to content
Open access

Site-specific immune remodeling underlies resistance to dual immune checkpoint blockade in metastatic colorectal cancer

Oct 2026 · medRxiv · 0 citations
Medicine

TL;DR

Findings show that resistance to ICI in liver metastases arises from tissue-specific misdirection of immune activation away from productive antitumor immunity, identifying multicellular coordination of the immune response in the metastatic microenvironment as a determinant of therapeutic efficacy.

Read PDF

Similar papers

Review Open access Sep 2026

Multipathway pharmacological interventions targeting liver-derived immune resistance in colorectal cancer liver metastasis

Immune checkpoint inhibitors provide durable benefit in mismatch repair-deficient colorectal cancer, but most microsatellite-stable tumors remain resistant, particularly in the presence of liver metastases. Immune resistance in colorectal cancer liver metastasis reflects both baseline MSS-CRC mechanisms, including low...

Miao Chen, Shan-Qing Qin, Yi-Feng Zhan et al. · 0 citations
Oct 2026

Epigenetic Priming Sensitizes Metastatic Breast Cancer to Checkpoint Blockade by Rewiring the Tumor-Immune Microenvironment.

Work using metastatic mouse models shows that the antitumor response is multifactorial, comprising downregulation of myeloid-mediated CD8+ T-cell suppression along with increased B-cell and plasma cell activation, antibody production, and tertiary lymphoid structure (TLS) maturation.

Y. Senent, R. Manguso · 0 citations
Open access Sep 2026

Neoantigen-reactive CD8+ T cell engagement marks exceptional survivors of pancreatic cancer

Pancreatic cancer (PC) is largely refractory to immune checkpoint blockade (ICB), although homologous recombination-deficient (HRD) tumors may derive benefit. In the POLAR trial of maintenance pembrolizumab plus olaparib after platinum-based chemotherapy for metastatic PC, responses remained heterogeneous. To define de...

M. Hilmi, J. Schoenfeld, Wilson H. McKerrow et al. · 0 citations
Review Open access Jan 2026

Prostate Cancer Therapy via Inhibition of Negative Immune Regulation

Prostate cancer exhibits complex pathophysiology, rendering its management arduous due to heterogeneity and recalcitrance toward conventional therapeutics. The increasing focus on immune checkpoint inhibitors for treatment stems from the limited existing therapeutic approaches and the impressive effectiveness of these...

S. Dutta, P. Sengupta, Ujjayita Chowdhury et al. · 0 citations
Sep 2026

Abstract B096: Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer

It is suggested that productive immunotherapy responses in PDAC require not only tumor-reactive T cells, but also a stromal-vascular niche capable of supporting their recruitment, recirculation and persistence.

Sarah Kang, M. Parikh, Leontios Pappas et al. · 0 citations
Review Open access Oct 2026

Immune Checkpoint Inhibitor Resistance in Genitourinary Cancers: Mechanisms, Biomarkers, and Emerging Therapeutic Strategies

Overall, ICI resistance in GU cancers emerges as a multidimensional phenomenon with distinct biological drivers across tumor subtypes; precision combinations targeting both intrinsic tumor factors and the immunosuppressive TME represent the most promising avenue to overcome resistance, and standardization of composite...

A. Chaux · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.